Advertisement
Singapore markets open in 17 minutes
  • Straits Times Index

    3,265.95
    +1.42 (+0.04%)
     
  • S&P 500

    5,214.08
    +26.41 (+0.51%)
     
  • Dow

    39,387.76
    +331.36 (+0.85%)
     
  • Nasdaq

    16,346.26
    +43.46 (+0.27%)
     
  • Bitcoin USD

    62,797.56
    +1,416.80 (+2.31%)
     
  • CMC Crypto 200

    1,350.75
    +50.65 (+3.89%)
     
  • FTSE 100

    8,381.35
    +27.30 (+0.33%)
     
  • Gold

    2,355.20
    +14.90 (+0.64%)
     
  • Crude Oil

    79.64
    +0.38 (+0.48%)
     
  • 10-Yr Bond

    4.4490
    -0.0430 (-0.96%)
     
  • Nikkei

    38,686.56
    +612.58 (+1.61%)
     
  • Hang Seng

    18,537.81
    +223.91 (+1.22%)
     
  • FTSE Bursa Malaysia

    1,601.22
    -3.53 (-0.22%)
     
  • Jakarta Composite Index

    7,088.79
    -34.81 (-0.49%)
     
  • PSE Index

    6,542.46
    -116.72 (-1.75%)
     

Nkarta to Participate in Upcoming Investor Conferences

Nkarta, Inc.
Nkarta, Inc.

SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in two upcoming investor conferences:

Needham Virtual Healthcare Conference
April 9, 2024
1:30 p.m. ET – fireside chat

Canaccord Genuity Horizons in Oncology Virtual Conference
April 15, 2024
1:00 p.m. ET – panel discussion

A simultaneous webcast of each event will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days.

ADVERTISEMENT

About Nkarta
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at www.nkartatx.com.

Nkarta Media/Investor Contact:
Greg Mann
Nkarta, Inc.
gmann@nkartatx.com